Featured

Status

Health Topics

Any Category
Clear Filters

Search Clinical Trials

400 Results
Completed
Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy
Tumor cells from subjects with high-risk neuroblastoma will be obtained at the time of presentation and initial diagnosis, during routine surveillance of bone marrow disease status, or at the time …
Unknown Status
Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
PROTOCOL OUTLINE: Patients are assigned to one of 6 study groups. Patients receive infusions of stable isotope tracers: [15N]urea IV beginning at -12 hours and continuing over 22 hours to …
Baylor Role: Collaborator
Completed
Stem Cell Transplant to Treat Patients With Systemic Sclerosis
Before the transplant the research participant will receive daily G-CSF (Neupogen) for 5-6 days. This medication will help to stimulate the production of white blood cells (WBC) that will be …
Baylor Role: Lead Sponsor
Completed
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
Before starting in the treatment part of this study, leukemia cells and skin fibroblasts will be collected from the patient - called "procurement" - to allow us to make the …
Baylor Role: Lead Sponsor
Completed
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis
To participate in this study, patients will need to have a central line (a thin plastic catheter or tube that is placed during surgery into one of the large veins …
Baylor Role: Lead Sponsor
Completed
Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
This study was conducted in three phases. The first phase spanned from 1998-2003 (PubMed ID:14706961; PubMed ID: 12915495) and the second phase spanned from 2003-2007 (PubMedID: 18401289; PubMed ID: 17698577). …
Baylor Role: Lead Sponsor
Completed
Study of Irinotecan on a Weekly Schedule in Children
Irinotecan will be given intravenously (into the vein) over 90 minutes for four weeks in a row. This cycle may be repeated in six weeks as long as the cancer …
Baylor Role: Lead Sponsor
Completed
Vector Delivery of the IL-12 Gene in Men With Prostate Cancer
The development of a clinical trial for gene therapy in prostate cancer will be coordinated with our collaborators at Baylor involved in similar studies in order to facilitate the approval …
Baylor Role: Lead Sponsor
Completed
Valacyclovir in Immunocompromised Children
Patients with shingles: Patients with shingles will receive oral Valacyclovir three times a day for 5 to 10 days. For the first 24 hours of treatment, patients will be admitted …
Baylor Role: Lead Sponsor
Completed
Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL
The investigators have grown neuroblastoma cells in the laboratory and put into them two specially produced mouse viruses (retroviruses) that carry the lymphotactin and the IL-2 gene. These lymphotactin and …
Baylor Role: Lead Sponsor